中国药企最大手笔海表并购! 复星医药并购印度药企Gland Pharma
分类：
公司新闻
作者： 复星医药
起源：
颁布功夫：2016-07-29 19:01
中国药企最大手笔海表并购！
复星医药拟斥资逾12亿美元并购印度当先注射剂药企GlandPharma，加快国际化过程 。
2016年7月28日，上海复星医药 (集团) 股份有限公司 (简称“复星医药”，股份代码: 600196.SH, 02196.HK) 布告称，拟通过控股子公司出资不超过126,137万美元收购Gland Pharma Limited（简称“Gland Pharma”）约86.08%的股权（以下简称“本次买卖”），其中蕴含收购方将凭据Gland 的依诺肝素产品在美国上市销售情况所支付的不超过5,000万美元的或有对价 。这是迄今中国造药企业买卖金额最大的海表并购案 。
本次买卖实现后，Gland Pharma的总部将持续设立在印度城市海德拉巴 。Gland Pharma的现任CEO及COO将持续留任，CEO及其父亲（公司首创人）仍将留在董事会 。
复星医药国际化沉要里程碑
复星医药董事长陈启宇暗示：“Gland Pharma有一支优良的治理团队，此前在KKR的强力支持下，业务发展极度迅速，已成长为拥有国际影响力的印度注射剂当先企业 。并购GlandPharma将成为复星医药造药工业实现国际化发展的一个沉要的里程碑，加快复星医药的国际化过程 。中国和印度在造药领域有很强的互补性 。以复星医药和Gland Pharma为代表的中印药企的资源嫁接将有利于推动中国药企在研发创新及仿造药出口等方面的国际化措施 。”
印度首家获美国FDA核准的注射剂药企
Gland Pharma成立于 1978 年，总部位于印度海德拉巴，重要从事注射剂药品的出产造作业务 。Gland Pharma是印度第一家获得美国FDA核准的注射剂药品出产造作企业，并获得全球各大律例市场的GMP认证，其业务收入重要来自于美国和欧洲 。Gland Pharma目前重要通过共同开发、引进许可，为全球各大型造药公司提供注射剂仿造药品的出产造作服务等 。作为少数专业从事出产造作注射剂药品的公司之一，Gland Pharma在印度市场同类公司中处于当先职位 。
启发生物医药全球市场
本次买卖实现后，将有助于推动复星医药的药品造作业务的产业升级、加快国际化过程、提升在注射剂市场的占有率 。同时，复星医药将借助Gland Pharma自身的研发能力及印度市场特有的仿造药政策优势，嫁接复星医药已有的生物医药创新研发能力，实现产品线的整合及协同，积极启发印度及其他市场的业务，从而扩大药品造作与研发业务的规模 。
布告也提醒了有关风险，本次买卖还须获得复星医药股东大会、Gland Pharma股东大会、中国境内有关主管部门境表投资核准以及其他国度主管部门（蕴含但不限于印度反垄断、印度表国投资、美国反垄断等主管部门）的核准 。
China’s Fosun Pharma to Sign Agreement for over US$ 1.2Billion in Gland Pharma Acquisition
SHANGHAI – [July 28, 2016] – Shanghai FosunPharmaceutical (Group) Co. Ltd. (together with its subsidiaries, “FosunPharma”), a leading Chinese healthcare provider (stock code: 600196.SH,02196.HK), today announced the signing of a definitive agreement under whichFosun Pharma will acquire an approximate [86.08%] stake in Gland Pharma for nomore than [US$ 1261.37 million], including paying no more than [US$ 50 million]contingent consideration for Gland’s Enoxaparin sales in the U.S. market. Thisis, so far, the largest overseas acquisition of a Chinese pharmaceuticalcompany.
Following the close of the transaction, Gland Pharma willremain headquartered in Hyderabad. P.V.N. Raju, Founder of Gland Pharma, andhis son, Dr. Ravi Penmetsa, will continue to be on the Board, and Dr. Penmetsawill continue to serve as Managing Director and CEO. The family will retain astake in Gland Pharma.
Mr. Chen Qiyu, chairman of Fosun Pharma said, “GlandPharma’s management team, along with the support from KKR, has done atremendous job of growing the business to become the global leader in GenericsInjectables Industry. The deal will greatly strengthen Fosun Pharma’s global presenceand accelerate our speed of internationalization. It will enable us to providemore high quality products and services to our patients worldwide. Fosun Pharmais dedicated to implementing our investment model of ‘Combining China’s GrowthMomentum with Global Resources’ with the win-win cooperation with Gland Pharma.”
Established in 1978 and based in Hyderabad, Gland Pharmadevelops and manufactures generic injectables for use in nearly 90 countries onfive continents, with a focus on the Indian and US markets. In 2003, GlandPharma became the first company in India to get US Food and Drug Administration(“FDA”) approval for pharmaceutical liquid injectable products. Gland Pharma’sworld-class manufacturing facilities have also received approvals from a numberof key medical regulatory agencies around the globe including those inAustralia, Germany, and the UK, as well as the World Health Organization(“WHO”).
The transaction will promote Fosun Pharma’s developmentby upgrading pharmaceutical manufacturing, speeding up internationalizationprogress and increasing market share in injectables field. The twopharmaceutical manufacturers are expected to integrate production lines andsynergize innovation in developing biopharmaceutical products. Fosun Pharmawould also be able to further explore the international market by leveragingGland Pharma’s research capability and India’s preferential policies upongeneric drugs.
The transaction is subject to customary regulatoryapprovals. Further details of the transaction are not disclosed.
有关新闻
■
规范诊疗破难题 聚力攻坚护健全——耐药结核病BPaL/M规划规范化临床建设单元师资培训班在武汉成功进行
—
2026-05-13
■
普惠升级！沈阳J9集团造药贝达喹啉获批——国内BPaL/M规划全产品供给企业
■
中国抗结核新篇章！首例6个月BPaL规划落地，耐药结核医治迎来革命性突破！
■
是的！我们能够终结结核：更普惠的医治，让更多患者看得见但愿
